WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 4001 Infant (under 12 months) mortality rate: 532
GDP / capita (US$): 9791 Child (under 5 years) mortality rate: 702

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 4'503  4'397  4'294  4'190  4'080  2'892  2'103  1'893 
Births 156  154  152  150  148  119  95  93 
Surviving infants 148  145  143  141  138  105  80  79 
Pop. less than 5 years 701  693  686  678  668  496  371  348 
Pop. less than 15 years 1'905  1'873  1'841  1'806  1'764  1'250  948  850 
Female 15-49 years 1'060  1'030  1'002  976  948  676  473  428 

Number of reported cases

(Click for retrospective incidence data for Liberia)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  1'060  34  43  279  5'977  6'567 
Mumps
ChartChart
 
Pertussis
ChartChart
  281  62 
Polio*
ChartChart
  98 
Rubella
ChartChart
  39 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  12  152  207 
Tetanus (total)**
ChartChart
  12  228  307 
Yellow fever
ChartChart
  17  137 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Liberia)
Vaccine year result method % card seen                                                
BCG 2012  94  DHS   58  74  73  87  85  85  45 
DTP1 2012  91  DHS   58  77  74  97  99*  86 
DTP3 2012  71  DHS   58  65  63  89  93  77  48 
DTP4         
IPV1         
HepB_BD         
HepB3 2012  71  DHS   58  65  63  89  93  77 
Hib3 2012  71  DHS   58  65  63  89  93  77 
JapEnc         
MCV1          64  58  74  80  71  52 
MCV2         
PCV1          72  90 
PCV3          56  45 
Pol3 2012  70  DHS   58  65  62  88  93  77  52 
Rota1         
RotaC         
Rubella1         
TT2plus 1994  77  MICS     63  68  76  74  74  25 
PAB         
VAD1          49  25  58  43  56  26 
YFV 2012  73  DHS   58  56  54  73  78  70 
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Liberia)
BCG
ChartChart
  74  73  87  85  85  78 
DTP1
ChartChart
  77  74  97  92  86  80 
DTP3
ChartChart
  52  50  76  80  77  46 
HepB3
ChartChart
  52  50  76  80  77 
HepB_BD
ChartChart
 
Hib3
ChartChart
  52  50  76  80  77 
IPV1
ChartChart
 
MCV1
ChartChart
  64  58  74  80  71  63 
MCV2
ChartChart
 
PAB
ChartChart
  89  89  91  91  91  51  33 
PCV3
ChartChart
  56  45 
Pol3
ChartChart
  52  49  75  80  77  56 
RCV1
ChartChart
 
RotaC
ChartChart
 
YFV
ChartChart
  56  54  73  78  70 

Number of districts in the country 15  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 7
From 80 to 89% 13
From 50 to 79% 73
Less than 50% 7
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
HPV 10 years (2 doses); No From April 2016
IPV 14 weeks; Yes From January 2018
Measles 9 months; Yes
OPV birth; 6, 10, 14 weeks; Yes
Pneumo_conj 6, 10, 14 weeks; Yes
Rotavirus 6, 10, 14 weeks; Yes From April 2016
TT 14 years; +1, +6 months; +1, +1 years; Yes and pregnant women
VitaminA 6-11 months; Yes
YF 9 months; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2011-2015  2011-2015  2011-2015  2011-2015  2011-2015  2006-2010  2006-2010 
Nº of districts with microplans that include activities to raise immunization coverage number 15  15  15  15  15  15 

System performance

Total Nº districts in country number 15  15  15  15  15  15  15 
Nº districts with DTP3 coverage >=80% number 13  14  13  14 
% of districts with DTP3 coverage >=80% From 0 to 100% 13  87  93  53  47  87  93 
Nº districts with measles (MCV1) coverage >=95% number 10  12 
% of districts with MCV1 coverage >=95% From 0 to 100% 13  13  67  80 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  Yes  Yes  Yes  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR No  Yes  Yes  Yes  No    Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 28         

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.